Nivolumab (Opdivo®) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models. BioSim™ Nivolumab ELISA kit has been developed for specific quantification of Nivolumab concentration in human serum or plasma with high sensitivity and reproducibility.
产品特点
• Easy, convenient, sensitive and time-saving method to measure the level of Nivolumab in human serum and plasma.
• Detection Range: 30 - 3000 ng/ml
• Sensitivity: 10 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
• Cross Reactivity: Except for Nivolumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins
